Protease inhibitor therapy post-liver transplantation in the treatment of hepatitis C virus infection.
作者信息
Nair Satheesh P
机构信息
Professor of Medicine Director of Transplant Hepatology University of Tennessee Health Science Center Memphis, Tennessee.
出版信息
Gastroenterol Hepatol (N Y). 2013 Jun;9(6):388-90.
Abstract
摘要
相似文献
1
Protease inhibitor therapy post-liver transplantation in the treatment of hepatitis C virus infection.肝移植后蛋白酶抑制剂疗法用于治疗丙型肝炎病毒感染。
Gastroenterol Hepatol (N Y). 2013 Jun;9(6):388-90.
2
Treatment of chronic hepatitis C virus infection after liver transplantation.肝移植后慢性丙型肝炎病毒感染的治疗。
Dig Liver Dis. 2013 Sep 30;45 Suppl 5:S349-54. doi: 10.1016/j.dld.2013.07.014.
3
[Diagnosis, treatment, and follow-up of hepatitis C-virus related liver disease. Hungarian national consensus guideline].[丙型肝炎病毒相关肝病的诊断、治疗及随访。匈牙利国家共识指南]
Orv Hetil. 2014 Mar;155 Suppl:3-24. doi: 10.1556/OH.2013.29893.
4
Natural history of hepatitis C following liver transplantation.肝移植后丙型肝炎的自然史。
Curr Opin Infect Dis. 2004 Aug;17(4):363-71. doi: 10.1097/01.qco.0000136934.06039.01.
5
[Side-effects of pegylated interferon plus ribavirin therapy with or without protease inhibitor direct acting antiviral agents during treatment of chronic hepatitis C virus infection].[聚乙二醇干扰素联合利巴韦林治疗慢性丙型肝炎病毒感染期间加用或不加用蛋白酶抑制剂直接抗病毒药物的副作用]
Orv Hetil. 2011 Dec 11;152(50):1997-2009. doi: 10.1556/OH.2011.29266.
6
Hepatitis C virus treatment and liver transplantation in the era of new antiviral therapies.丙型肝炎病毒治疗与新型抗病毒疗法时代的肝移植。
Curr Opin Organ Transplant. 2012 Jun;17(3):216-24. doi: 10.1097/MOT.0b013e3283534d64.
7
[Hepatitis C and liver transplantation: fibrosis progression and treatment. Or how to improve management].[丙型肝炎与肝移植：纤维化进展与治疗。或如何改善管理]
Gastroenterol Clin Biol. 2006 Nov;30(11):1281-95. doi: 10.1016/s0399-8320(06)73536-9.
8
Occurrence of post-transplant lymphoproliferative disorders among over thousand adult recipients: any role for hepatitis C infection?超过千名成年受者中移植后淋巴细胞增生性疾病的发生情况：丙型肝炎感染有何作用？
Eur J Gastroenterol Hepatol. 2006 Oct;18(10):1065-70. doi: 10.1097/01.meg.0000231752.50587.ae.
9
Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience.肝移植后应用蛋白酶抑制剂治疗丙型肝炎的安全性和疗效：多中心经验。
J Hepatol. 2014 Jan;60(1):78-86. doi: 10.1016/j.jhep.2013.08.018. Epub 2013 Aug 29.
10
Hepatitis B virus surface mutations associated with infection after liver transplantation.与肝移植后感染相关的乙型肝炎病毒表面突变
J Hepatol. 1996 Jan;24(1):8-14. doi: 10.1016/s0168-8278(96)80179-6.
引用本文的文献
1
Direct-acting antiviral agent efficacy and safety in renal transplant recipients with chronic hepatitis C virus infection: A PRISMA-compliant study.直接作用抗病毒药物在慢性丙型肝炎病毒感染肾移植受者中的疗效与安全性：一项遵循PRISMA规范的研究。
Medicine (Baltimore). 2017 Jul;96(30):e7568. doi: 10.1097/MD.0000000000007568.
2
Tolerability and effectiveness of sofosbuvir and simeprevir in the post-transplant setting: systematic review and meta-analysis.索磷布韦和西米普韦在移植后环境中的耐受性和有效性：系统评价和荟萃分析。
BMJ Open Gastroenterol. 2016 Jan 4;3(1):e000066. doi: 10.1136/bmjgast-2015-000066. eCollection 2016.
3
Drug-drug interactions with oral anti-HCV agents and idiosyncratic hepatotoxicity in the liver transplant setting.肝移植环境中口服抗丙型肝炎病毒药物的药物相互作用及特异质性肝毒性
J Hepatol. 2014 Apr;60(4):872-84. doi: 10.1016/j.jhep.2013.11.013. Epub 2013 Nov 23.
本文引用的文献
1
Management of the transplant recipient with chronic hepatitis C.慢性丙型肝炎移植受者的管理。
Clin Liver Dis. 2013 Feb;17(1):73-91. doi: 10.1016/j.cld.2012.09.013.
2
Host genomics and HCV treatment response.宿主基因组学与 HCV 治疗反应。
J Gastroenterol Hepatol. 2012 Feb;27(2):212-22. doi: 10.1111/j.1440-1746.2011.06918.x.
Zotero 插件